Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762369 | 1.00 | ADAMTS5 (0.50) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL17830319 | 1.00 | ADAMTS5 (0.50) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| D-Glutamate SCHEMBL11414446 | 0.86 | GRM8 (0.53) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL1679984 | 0.83 | NPSR1 (0.50) | ADAMTS5ADAMTS4NPSR1TDP1ABL1 | |
| SCHEMBL31707085 | 0.83 | NPSR1 (0.50) | ADAMTS5ADAMTS4NPSR1TDP1ABL1 | |
| SCHEMBL17819214 | 0.82 | ADAMTS5 (0.46) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL17819216 | 0.82 | ADAMTS5 (0.46) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL13803876 | 0.82 | ADAMTS5 (0.46) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL13176600 | 0.82 | ADAMTS5 (0.46) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL18123425 | 0.82 | GAA (0.46) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| WO-2016094846-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094846-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | ADAMTS5 3260/4885ADAMTS4 3707/4885ADAM17 2315/4885 |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | ADAMTS5 162/4885ADAMTS4 169/4885ADAM17 472/4885 |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | ADAMTS5 162/4885ADAMTS4 169/4885ADAM17 472/4885 |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885ADAMTS4 2/4885ADAM17 10/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | ADAMTS5 3260/4885ADAMTS4 3707/4885ADAM17 2315/4885 |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885ADAMTS4 2/4885ADAM17 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.